Brief: Bile Tract Cancer Expansion Study Opens Following Clearance Of Imugene’S Mast Trial High Dose Cohort
15/04/2024 23:27
April 15 (Reuters) - Imugene Ltd IMU.AX :
* BILE TRACT CANCER EXPANSION STUDY OPENS FOLLOWING
CLEARANCE OF
IMUGENE’S MAST TRIAL HIGH DOSE COHORT
Source text for Eikon: ID:nGNX9sWxWB
Further company coverage: IMU.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Imugene
See all newsAustralia's Imugene rises on fresh responses in blood cancer drug trial
Brief: Imugene Ltd Says Leslie Chong Resigns As CEO
Australia's Imugene loses most in over 8-years on discounted placement
Brief: Imugene To Raise A$11.12 Million Via Placement At A$0.095 Per Share
Brief: Imugene Requests Trading Halt Pending Proposed Capital Raising Announcement